A study of safety and efficacy of ipragliflozin in the treatment of diabetes in Kanagawa - ASSIGN-K

The Study Group of the Diabetes Committee, Kanagawa Physicians Association0 个研究点目标入组 500 人开始时间: 2014年6月30日最近更新: 2023年10月17日

试验速览

Ipragliflozin Improves Glycemic Control and Decreases Body Fat in Patients With Type 2 Diabetes Mellitus. Kawata T, et al. J Clin Med Res. 2017 Jul; 9(7): 586-595. 2. Efficacy and Safety of Ipragliflozin in Japanese Patients With Type 2 Diabetes: Interim Outcome of the ASSIGN-K Study. Iizuka T, et al. J Clin Med Res. 2016 Feb; 8(2): 116-125.

•1) Has hypersensitivity to ipragliflozin or any other excipient of ipragliflozin 2) With severe ketosis, diabetic coma, or precoma within 6 months 3) With severe infection, pre or post surgery, and serious trauma 4) With severe renal dysfunction 5) Considered as inadequate by the investigator 6) Is pregnant or possibility of pregnant, planning or possibility of pregnant during research (Except for acceptable method of birth control, surgically sterilized, and postmenopause), or nursing

发起方

The Study Group of the Diabetes Committee, Kanagawa Physicians Association